Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
Over 1,000 cancer treatment protocols
Medical Oncology, Hematology, Bone Marrow Transplantation
With administration details, lab parameters, indications, and summarized references
Updated monthly to include latest approvals and major papers
Reviewed by Medical Oncologists and Hematologists
New Indication: Sunvozertinib for Untreated Advanced NSCLC with EGFR Exon 20 Insertions
In this international phase 3 trial, first-line sunvozertinib significantly improved progression-free survival and objective response rate compared to carboplatin-pemetrexed chemot
New Reference: Lorlatinib for ALK+ NSCLC
This 7-year update of the CROWN trial demonstrated that lorlatinib maintained unprecedented long-term progression-free survival benefit compared to crizotinib in advanced ALK-posit
New Reference: Encorafenib-Cetuximab with FOLFIRI in bRAF V600E Metastatic Colorectal Cancer
In this phase III randomized study, encorafenib plus cetuximab combined with FOLFIRI significantly improved objective response rate, progression-free survival, and overall survival
New Protocol: Camrelizumab with Apatinib for Chordoma
This phase II trial demonstrated that the combination of camrelizumab and apatinib in refractory chordoma achieved an objective response rate of 24.2% by RECIST and 48.5% by Choi c
New Reference: Cabozantinib with Nivolumab and Ipilimumab for Interm/High Risk RCC
The phase III COSMIC-313 study demonstrated that adding cabozantinib to nivolumab and ipilimumab significantly improved progression-free survival and objective response rate in pat
New Protocol: Oral Decitabine/Cedazuridine with Venetoclax for AML
This single-centre phase 2 study demonstrates that oral ASTX727 plus venetoclax is effective and tolerable in older or unfit patients with acute myeloid leukemia, inducing rapid re
New Indication: Zongertinib for HER2-Mutated Advanced NSCLC
In this phase 1b multicohort study, first-line zongertinib demonstrated a 76% objective response rate with durable responses and a median progression-free survival of 14.4 months i
New Protocol: Periop Toripalimab with Chemotherapy for Esophageal Cancer
In this phase II randomized trial with 3-year follow-up, perioperative toripalimab plus chemotherapy significantly improved event-free survival and overall survival compared to che
New Reference: Retifanlimab with Carboplatin – Paclitaxel for Advanced Anal Cancer
In this phase 3 randomized trial of patients with advanced squamous cell carcinoma of the anal canal, retifanlimab combined with carboplatin-paclitaxel significantly improved progr
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.
